Rheumatoid Arthritis eJournal Club
   

Applying Research to Your Practice: Focus on Nonbiologic DMARDs in 2009
 
Release Date: August 31, 2009 Expiration Date: August 31, 2010

Technical Requirements
(will appear in new window)
 
Estimated Time of Completion 60 minutes
Description / Overview The purpose of this activity is to discuss treatment options for a patient with rheumatoid arthritis (RA), including recent evidence highlighting the value of nonbiologic disease-modifying antirheumatic drugs (DMARDs) in current therapy.
Objectives On completion of this activity, participants should be able to:
  1. Describe the rationale for early and aggressive treatment when treating a patient with RA, including evidence for use of nonbiologic DMARDs.
  2. Discuss the value and type of outcome measures that can be used in determining response to biologic and nonbiologic DMARDs.
  3. Outline treatment options for a patient with RA using the concept of tight control.
Target Audience This activity is directed to rheumatologists and primary care physicians who treat patients with RA.
Accreditation The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, Ohio
Author / Faculty Yusuf Yazici, MD
Assistant Professor of Medicine
New York University School of Medicine
Director, Seligman Center for Advanced Therapeutics
New York University Hospital for Joint Diseases
New York, New York
Faculty Disclosure In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:
Leonard Calabrese, DO
  Consulting: Abbott Laboratories; Amgen Inc.; Centocor, Inc.; Elan Pharmaceuticals, Inc.; Genentech, Inc.; Roche Laboratories, Inc.
 
  Research: Centocor, Inc.
 
  Teaching and Speaking: Amgen Inc.; Genentech, Inc.
 
Yusuf Yazici, MD
  Consulting: Bristol-Myers Squibb Company; Celgene Corporation; Centocor, Inc.;
Roche Laboratories, Inc.; UCB

The Cleveland Clinic Foundation Center for Continuing Education acknowledges:

This activity is supported by an educational donation provided by Amgen.
This activity is supported by an educational grant from Bristol-Myers Squibb Company.
This activity is supported by an educational grant from Centocor Ortho Biotech Services.
This activity is supported by an independent educational grant from Roche Laboratories, Inc.

This CME activity was produced by The Cleveland Clinic Foundation Center for Continuing Education,
the RJ Fasenmyer Center for Clinical Immunology and DIME.

CME Disclaimer